Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Trimerization of CD40L-specific affibody molecules using collagen domains enhances target binding and CD40 blockade.

Cellular and molecular life sciences : CMLS·2026
Same author

Combining bacterial display and protein language models to engineer a CD69-binding affibody for molecular imaging of immune activation.

Protein engineering, design & selection : PEDS·2026
Same author

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Journal of biological engineering·2026
Same author

Engineering affibody domains as anti-idiotypic masks for nivolumab-based prodrugs.

Protein engineering, design & selection : PEDS·2026
Same author

Increased affinity by dimerization of radiolabeled Affibody molecule ATH001 targeting PDGFRβ.

EJNMMI radiopharmacy and chemistry·2026
Same author

Tumour accumulation of anti-carcinoembryonic antigen affibody-albumin-binding domain fusion depends on domains' order.

International journal of biological macromolecules·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Moira Ek1, Johan Nilvebrant1, Per-Åke Nygren1

  • 1KTH Royal Institute of Technology, Stockholm, -, Sweden.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Los investigadores desarrollaron una miniproteína novedosa dirigida a la sortilina para aumentar los niveles de progranulina, ofreciendo una estrategia terapéutica prometedora para la demencia frontotemporal (DFT). Este enfoque basado en affibody muestra potencial como alternativa rentable a los tratamientos con anticuerpos.

Palabras clave:
demencia frontotemporalprogranulinasortilinaaffibodyminiproteínadesarrollo de fármacosterapia génica

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Biotecnología
  • Neurociencia
  • Descubrimiento de Fármacos

Sus antecedentes:

  • Las mutaciones en el gen de la progranulina (GRN) causan el 5-10% de los casos de demencia frontotemporal (DFT).
  • Estas mutaciones disminuyen los niveles de progranulina, un factor clave en la patogénesis de la DFT.
  • La inhibición de la degradación de la progranulina mediada por sortilina es una estrategia terapéutica potencial para la DFT-GRN.

Objetivo del estudio:

  • Desarrollar una miniproteína novedosa basada en affibody anti-sortilina como alternativa a las terapias basadas en inmunoglobulinas.
  • Evaluar la eficacia de la miniproteína desarrollada para aumentar los niveles extracelulares de progranulina.

Principales métodos:

  • Se identificaron affibodies que se unen a la sortilina mediante tecnología de phage display.
  • Los affibodies se fusionaron genéticamente con péptidos del C-terminal de la progranulina para crear miniproteínas.
  • Se evaluó la afinidad, estructura, estabilidad y capacidad de elevación de progranulina de la miniproteína in vitro.

Principales resultados:

  • Se desarrolló con éxito un candidato a miniproteína principal con una afinidad de 185 pM por la sortilina.
  • La fusión affibody-péptido aumentó significativamente los niveles extracelulares de progranulina en ensayos basados en células.
  • La miniproteína demostró una potencia comparable a la latozinemab en estudios funcionales.

Conclusiones:

  • Las miniproteínas basadas en affibody desarrolladas son eficaces para aumentar los niveles de progranulina in vitro.
  • Estas miniproteínas representan una alternativa viable y potencialmente más rentable a los anticuerpos para la DFT-GRN.
  • El pequeño tamaño y la naturaleza no inmunogénica ofrecen ventajas para aplicaciones terapéuticas.